Veristat, Aegerion Partner
News Sep 23, 2016
Veristat has announced the signing of a Preferred Provider Agreement (PPA) with Aegerion Pharmaceuticals Inc. (“Aegerion”) to the development and commercialization of innovative therapies for patients with debilitating rare diseases. Veristat has assisted Aegerion with US Food and Drug Administration, EU Market Authorization Application, and Japan Food and Drug Administration submission projects over the past 5 years.
Veristat will offer Aegerion clinical trial support including statistical consulting, biostatistical analysis, clinical data management, clinical monitoring, SAS programming, clinical protocol and study report writing, project management and the preparation of regulatory submission documents.
“Veristat has been a strong and dedicated collaborative partner and an extension of our project teams,” said Pamela Foulds, MD, Vice President of Clinical Development at Aegerion Pharmaceuticals.
“Veristat is thrilled to progress to this next phase in our working relationship with Aegerion,” stated Barbara Balser, VMD, Chief Scientific Officer at Veristat. “We feel like a true partner to Aegerion and are eager to continue to deliver quality expertise and services for their marketing applications.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019